Jump to content

Draft:Martin R. Schiller

From Wikipedia, the free encyclopedia
  • Comment: Note for future editors/reviewers. This autobiographical page was previously User:MartinRSchiller and then that page was moved directly to mainspace. Draftified as part of WP:NPP and I removed one user redirect but things may still be messed up. Ldm1954 (talk) 15:24, 2 October 2024 (UTC)
Martin R. Schiller, PhD
Martin R. Schiller
Born1963
New York
Organization(s)University of Nevada, Las Vegas ; Heligenics Inc.
Websitehttps://www.unlv.edu/people/martin-schiller

Martin R. Schiller (born 1963) is an American biochemist and molecular biologist. He is the Founder and Executive Director of the Nevada Institute of Personalized Medicine at the University of Nevada Las Vegas. Dr. Schiller is known for his research in Bioinformatics, Cell Signaling, and Genetics.

Early life and education

[edit]

Schiller was born in Glen Cove, New York, and raised in Huntington, New York. Schiller received a BS degree in Biochemistry from Hofstra University, New York. He attended Graduate School at Utah State University in Logan, Utah in 1987, graduating in 1991 with a PhD in Biochemistry. He trained under Elizabeth Baker to advance progress curve enzyme kinetics analytics with a generalized mechanism integrated rate equation.[1][2] Moving forward, He broadened his training across many related scientific disciplines. In three postdoctoral fellowships, Schiller worked on directed evolution under John Gerlt at the University of Maryland, College Park, Maryland, Peptide Prohormone processing of Proenkephalin[3][4][5][6][7][8] with Vivian Hook at the Uniformed Services University of the Health Sciences, Bethesda, Maryland, and Regulation of the secretory pathway[9][10][11][12][13] with Dick Mains and Betty Eipper in the Department of Neuroscience at The Johns Hopkins School of Medicine. In this latter postdoc he discovered lumicrine signaling in the secretory pathway.[14]

Academic career

[edit]

In 1997, Schiller was appointed as an assistant professor in the Departments of Pathology and Anesthesiology at The Johns Hopkins School of Medicine. He continued his work on the regulated secretory pathway[15][16] and collaborated with neuropathologist Peter Burger analyzing different types of brain tumors. His cDNA libraries were the first brain tumor libraries sequenced by the EST project.[17][18]

In 2000, he moved to the Department of Neuroscience in the UConn Health Center in Farmington, Connecticut. He worked on Rho GTPase signaling in nerve cells,[19][20][21][22][23][24] establishing a new RhoGEF (Guanine nucleotide exchange factors) regulatory mechanisms by SH3 domains[25] and recognizing a broad signaling architecture in which Receptor Tyrosine Kinases most often signal through RhoGEFs and Rho GTPases.[26] Related to signaling, his laboratory also built Minimotif Miner, a database and webtool to investigate short functional minimotifs.[27][28][29][30] The Minimotif Miner webtool was extended to launch HIVtoolbox to investigate molecular functions of HIV proteins and AIDS pathology.[31][32][33] He was promoted to Associate Professor at UConn Health Center.

In 2009, Schiller moved to the School of Life Sciences at the University of Nevada, Las Vegas and was promoted to Full Professor in 2011. He continued his work developing Minimotif Miner[34][35][36][37] and HIVToolbox.[38][39] The HIV Toolbox was used to design TALENs, later proved to be effective for gene editing and damaging the HIV genome in infected cells.[40][41] His work on Minimotifs in 2010-2014 culminated in being one of the first scientific labs to apply Support Vector Machines and Neural Networks to large biological datasets to predict new Minimotifs with high accuracy, an early predecessor to the emerging machine learning techniques.[42]

In 2014, Schiller became the founder and Executive Director of the Nevada Institute of Personalized Medicine at the University of Nevada, Las Vegas, initially supported by Brian Sandoval’s Nevada Government’s Office of Economic Development. Schiller has since maintained cultivated programmatic grants to support and growth the institute. Institute research has included applications of data science and machine learning to genetic and medical problems.

In 2016, Schiller was one of the first 5 faculty in the, at the time, new Kirk Kerkorian UNLV School of Medicine and played an important role in the early stages of its development.

His lab developed the first high accuracy and throughput GigaAssay assays system for molecular function and cell processes, which has been the lab focus for the last decade.[43][44][45][46] The synthesis for this new Biotechnology was driven by key observations from teaching a class about Great Biological discoveries, his research on minimotif screens, and helping to design and set up a Next Generation Sequencing Core called the Genome Acquisition and Analysis core in the Nevada Institute of Personalized Medicine.

The GigaAssay has generated several basic science discoveries, was used to commercialize the GigaAssay in https://www.Heligenics.com, in which it was used to discover new a new prognostic for breast cancer, companion diagnostic for drug selection,[47] and discovery of new Biologics for the Interferon gene family. The GigaAssay also revealed that a high percentage of synonymous mutations are not silent - Variants of Uncertain Silence.,[48][49] which has implications for genetic diagnostic tests.

Commercial and business career

[edit]

Beni and Sons Painting. As a 14-year old in 1977, Schiller founded a painting company that did interior and exterior painting until 1981 when it was closed.

The Yeast Culture Kit Company Inc. At the onset of United States Microbrewery revolution in 1993, he founded this company that produced kits to culture brewing yeast for microbreweries and pure 1 liter yeast cultures for startup microbreweries throughout the world. He authored the keynote article in the first issue of Brewing Techniques.[50] The company was sold in 1995.

Schiller Realty Group, LLC. In 1992, Schiller founded this real estate company the acquired and rented private and commercial properties, and acquired and developed properties into building lots. Assets were transferred to the Silver Streak Realty, LLC real estate holding company, with some later being donated for land conservation.

Food Genes and Me, LLC. In 2016 Schiller founded and developed this personalized diet company. The we application takes in a recreational genetic file from 23andme or Ancestry and calculated a personalized diet based on data from the USDA and published and annotated genetic information for association of diet with disease.[51] In 2018, this company was donated to N Sanchez Medical Research Corporation

Heligenics Inc. In 2017, Schiller founded the Biotechnology company. Heligenics' technology analyzes massive Gene Mutation Libraries (GMLs) with its proprietary tool, GigaAssay™, to produce a comprehensive MEGA-Map. This system measures all genetic variants and tests their functional impact en masse in live human cells.[52][53][54] The company's products are improved diagnostics and companion diagnostics,[55] data for segmenting participants for truly precision clinical trials and discovery of novel Biologics, including Biosimilars, New Drugs, and Multi-functional Chimera. The company was converted to a C-Corp in 2019, funded in 2020, and is continuing its operations.

References

[edit]
  1. ^ Schiller, M. R., L. D. Holmes, and E. A. Boeker. “Analysis of Wild-Type and Mutant Aspartate Aminotransferases Using Integrated Rate Equations.” Biochimica Et Biophysica Acta 1297, no. 1 (September 13, 1996): 17–27. https://doi.org/10.1016/0167-4838(96)00083-0.
  2. ^ Holmes, L. D., M. R. Schiller, and E. A. Boeker. “Kinetic Analysis of Lactate Dehydrogenase Using Integrated Rate Equations.” Experientia 49, no. 10 (October 15, 1993): 893–901. https://doi.org/10.1007/BF01952605.
  3. ^ Schiller, M. R., L. Mende-Mueller, K. Moran, M. Meng, K. W. Miller, and V. Y. Hook. “‘Prohormone Thiol Protease’ (PTP) Processing of Recombinant Proenkephalin.” Biochemistry 34, no. 25 (June 27, 1995): 7988–95. https://doi.org/10.1021/bi00025a004.
  4. ^ Schiller, M. R., A. B. Kohn, L. M. Mende-Muelller, K. Miller, and V. Y. Hook. “Expression of Recombinant Pro-Neuropeptide Y, Proopiomelanocortin, and Proenkephalin: Relative Processing by ‘prohormone Thiol Protease’ (PTP).” FEBS Letters 382, no. 1–2 (March 11, 1996): 6–10. https://doi.org/10.1016/0014-5793(96)00083-x.
  5. ^ Hook, V. Y., M. R. Schiller, C. Nguyen, and S. Yasothornsrikul. “Production of Radiolabeled Neuropeptide Precursors by in Vitro Transcription and Translation.” Peptide Research 9, no. 4 (August 1996): 183–87.
  6. ^ Hook, V. Y., M. R. Schiller, and A. V. Azaryan. “The Processing Proteases Prohormone Thiol Protease, PC1/3 and PC2, and 70-kDa Aspartic Proteinase Show Preferences among Proenkephalin, Proneuropeptide Y, and Proopiomelanocortin Substrates.” Archives of Biochemistry and Biophysics 328, no. 1 (April 1, 1996): 107–14. https://doi.org/10.1006/abbi.1996.0149.
  7. ^ Hook, V. Y., M. R. Schiller, A. V. Azaryan, and N. Tezapsidis. “Proenkephalin-Processing Enzymes in Chromaffin Granules: Model for Neuropeptide Biosynthesis.” Annals of the New York Academy of Sciences 780 (March 22, 1996): 121–33. https://doi.org/10.1111/j.1749-6632.1996.tb15116.x.
  8. ^ Azaryan, A. V., M. R. Schiller, and V. Y. Hook. “Chromaffin Granule Aspartic Proteinase Processes Recombinant Proopiomelanocortin (POMC).” Biochemical and Biophysical Research Communications 215, no. 3 (October 24, 1995): 937–44. https://doi.org/10.1006/bbrc.1995.2554.
  9. ^ Ciccotosto, G. D., M. R. Schiller, B. A. Eipper, and R. E. Mains. “Induction of Integral Membrane PAM Expression in AtT-20 Cells Alters the Storage and Trafficking of POMC and PC1.” The Journal of Cell Biology 144, no. 3 (February 8, 1999): 459–71. https://doi.org/10.1083/jcb.144.3.459.
  10. ^ Darlington, D. N., M. R. Schiller, R. E. Mains, and B. A. Eipper. “Expression of RESP18 in Peptidergic and Catecholaminergic Neurons.” The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 45, no. 9 (September 1997): 1265–77. https://doi.org/10.1177/002215549704500910.
  11. ^ Darlington, D. N., M. R. Schiller, R. E. Mains, and B. A. Eipper. “The Expression of Regulated Endocrine-Specific Protein of 18 kDa in Peptidergic Cells of Rat Peripheral Endocrine Tissues and in Blood.” The Journal of Endocrinology 155, no. 2 (November 1997): 329–41. https://doi.org/10.1677/joe.0.1550329.
  12. ^ Schiller, M. R., R. E. Mains, and B. A. Eipper. “A Neuroendocrine-Specific Protein Localized to the Endoplasmic Reticulum by Distal Degradation.” The Journal of Biological Chemistry 270, no. 44 (November 3, 1995): 26129–38. https://doi.org/10.1074/jbc.270.44.26129.
  13. ^ Schiller, M. R., R. E. Mains, and B. A. Eipper. “A Novel Neuroendocrine Intracellular Signaling Pathway.” Molecular Endocrinology (Baltimore, Md.) 11, no. 12 (November 1997): 1846–57. https://doi.org/10.1210/mend.11.12.0024.
  14. ^ Schiller, M. R., R. E. Mains, and B. A. Eipper. “A Novel Neuroendocrine Intracellular Signaling Pathway.” Molecular Endocrinology (Baltimore, Md.) 11, no. 12 (November 1997): 1846–57. https://doi.org/10.1210/mend.11.12.0024.
  15. ^ Zhang, Guofeng, Hiroki Hirai, Tao Cai, Junnosuke Miura, Ping Yu, Hanxia Huang, Martin R. Schiller, William D. Swaim, Richard D. Leapman, and Abner L. Notkins. “RESP18, a Homolog of the Luminal Domain IA-2, Is Found in Dense Core Vesicles in Pancreatic Islet Cells and Is Induced by High Glucose.” The Journal of Endocrinology 195, no. 2 (November 2007): 313–21. https://doi.org/10.1677/JOE-07-0252.
  16. ^ Park, Y. S., E. Kawasaki, K. Kelemen, L. Yu, M. R. Schiller, M. Rewers, M. Mizuta, G. S. Eisenbarth, and J. C. Hutton. “Humoral Autoreactivity to an Alternatively Spliced Variant of ICA512/IA-2 in Type I Diabetes.” Diabetologia 43, no. 10 (October 2000): 1293–1301. https://doi.org/10.1007/s001250051525.
  17. ^ Xu, X., H. D. Joh, S. Pin, N. I. Schiller, C. Prange, P. C. Burger, and M. R. Schiller. “Expression of Multiple Larger-Sized Transcripts for Several Genes in Oligodendrogliomas: Potential Markers for Glioma Subtype.” Cancer Letters 171, no. 1 (September 28, 2001): 67–77. https://doi.org/10.1016/s0304-3835(01)00573-0.
  18. ^ Schiller, M. R. “Genes Expressed in the Mouse Pituitary Corticotrope AtT-20/D-16v Tumor Cell Line.” Pituitary 3, no. 3 (November 2000): 141–52. https://doi.org/10.1023/a:1011491324117.
  19. ^ Chakrabarti, Kausik, Rong Lin, Noraisha I. Schiller, Yanping Wang, David Koubi, Ying-Xin Fan, Brian B. Rudkin, Gibbes R. Johnson, and Martin R. Schiller. “Critical Role for Kalirin in Nerve Growth Factor Signaling through TrkA.” Molecular and Cellular Biology 25, no. 12 (June 2005): 5106–18. https://doi.org/10.1128/MCB.25.12.5106-5118.2005.
  20. ^ Gorbatyuk, Vitaliy Y, Martin R Schiller, Oksana I Gorbatyuk, Marek Barwinski, and Jeffrey C Hoch. “N-Terminal Dbl Domain of the RhoGEF, Kalirin.” Journal of Biomolecular NMR 52, no. 3 (March 2012): 269–76. https://doi.org/10.1007/s10858-012-9605-x.
  21. ^ May, Victor, Martin R. Schiller, Betty A. Eipper, and Richard E. Mains. “Kalirin Dbl-Homology Guanine Nucleotide Exchange Factor 1 Domain Initiates New Axon Outgrowths via RhoG-Mediated Mechanisms.” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 22, no. 16 (August 15, 2002): 6980–90. https://doi.org/20026718.
  22. ^ Penzes, Peter, Alexander Beeser, Jonathan Chernoff, Martin R. Schiller, Betty A. Eipper, Richard E. Mains, and Richard L. Huganir. “Rapid Induction of Dendritic Spine Morphogenesis by Trans-Synaptic ephrinB-EphB Receptor Activation of the Rho-GEF Kalirin.” Neuron 37, no. 2 (January 23, 2003): 263–74. https://doi.org/10.1016/s0896-6273(02)01168-6.
  23. ^ Schiller, Martin R., Anne Blangy, Jianping Huang, Richard E. Mains, and Betty A. Eipper. “Induction of Lamellipodia by Kalirin Does Not Require Its Guanine Nucleotide Exchange Factor Activity.” Experimental Cell Research 307, no. 2 (July 15, 2005): 402–17. https://doi.org/10.1016/j.yexcr.2005.03.024.
  24. ^ Schiller, Martin R., Francesco Ferraro, Yanping Wang, Xin-ming Ma, Clifton E. McPherson, Jacqueline A. Sobota, Noraisha I. Schiller, Richard E. Mains, and Betty A. Eipper. “Autonomous Functions for the Sec14p/Spectrin-Repeat Region of Kalirin.” Experimental Cell Research 314, no. 14 (August 15, 2008): 2674–91. https://doi.org/10.1016/j.yexcr.2008.05.011.
  25. ^ Schiller, Martin R., Kausik Chakrabarti, Glenn F. King, Noraisha I. Schiller, Betty A. Eipper, and Mark W. Maciejewski. “Regulation of RhoGEF Activity by Intramolecular and Intermolecular SH3 Domain Interactions.” The Journal of Biological Chemistry 281, no. 27 (July 7, 2006): 18774–86. https://doi.org/10.1074/jbc.M512482200.
  26. ^ Schiller, Martin R. “Coupling Receptor Tyrosine Kinases to Rho GTPases--GEFs What’s the Link.” Cellular Signalling 18, no. 11 (November 2006): 1834–43. https://doi.org/10.1016/j.cellsig.2006.01.022.
  27. ^ Balla, Sudha, Vishal Thapar, Snigdha Verma, Thaibinh Luong, Tanaz Faghri, Chun-Hsi Huang, Sanguthevar Rajasekaran, et al. “Minimotif Miner: A Tool for Investigating Protein Function.” Nature Methods 3, no. 3 (March 2006): 175–77. https://doi.org/10.1038/nmeth856.
  28. ^ Rajasekaran, Sanguthevar, Sudha Balla, Patrick Gradie, Michael R. Gryk, Krishna Kadaveru, Vamsi Kundeti, Mark W. Maciejewski, et al. “Minimotif Miner 2nd Release: A Database and Web System for Motif Search.” Nucleic Acids Research 37, no. Database issue (January 2009): D185-190. https://doi.org/10.1093/nar/gkn865.
  29. ^ Schiller, Martin R. “Minimotif Miner: A Computational Tool to Investigate Protein Function, Disease, and Genetic Diversity.” Current Protocols in Protein Science Chapter 2 (May 2007): Unit 2.12. https://doi.org/10.1002/0471140864.ps0212s48.
  30. ^ Vyas, Jay, Ronald J. Nowling, Mark W. Maciejewski, Sanguthevar Rajasekaran, Michael R. Gryk, and Martin R. Schiller. “A Proposed Syntax for Minimotif Semantics, Version 1.” BMC Genomics 10 (August 5, 2009): 360. https://doi.org/10.1186/1471-2164-10-360.
  31. ^ Sargeant, David, Sandeep Deverasetty, Yang Luo, Angel Villahoz Baleta, Stephanie Zobrist, Viraj Rathnayake, Jacqueline C. Russo, Jay Vyas, Mark A. Muesing, and Martin R. Schiller. “HIVToolbox, an Integrated Web Application for Investigating HIV.” PloS One 6, no. 5 (2011): e20122. https://doi.org/10.1371/journal.pone.0020122.
  32. ^ Sargeant, David P., Sandeep Deverasetty, Christy L. Strong, Izua J. Alaniz, Alexandria Bartlett, Nicholas R. Brandon, Steven B. Brooks, et al. “The HIVToolbox 2 Web System Integrates Sequence, Structure, Function and Mutation Analysis.” PloS One 9, no. 6 (2014): e98810. https://doi.org/10.1371/journal.pone.0098810.
  33. ^ Sargeant, David P., Michael W. Hedden, Sandeep Deverasetty, Christy L. Strong, Izua J. Alaniz, Alexandria N. Bartlett, Nicholas R. Brandon, et al. “The Geogenomic Mutational Atlas of Pathogens (GoMAP) Web System.” PloS One 9, no. 3 (2014): e92877. https://doi.org/10.1371/journal.pone.0092877.
  34. ^ Schiller, Martin R, Tian Mi, Jerlin Camilus Merlin, Sandeep Deverasetty, Michael R Gryk, Travis J Bill, Andrew W Brooks, et al. “Minimotif Miner 3.0: Database Expansion and Significantly Improved Reduction of False-Positive Predictions from Consensus Sequences.” Nucleic Acids Research, December 6, 2011. https://doi.org/10.1093/nar/gkr1189.
  35. ^ Lyon, Kenneth F., Xingyu Cai, Richard J. Young, Abdullah-Al Mamun, Sanguthevar Rajasekaran, and Martin R. Schiller. “Minimotif Miner 4: A Million Peptide Minimotifs and Counting.” Nucleic Acids Research 46, no. D1 (January 4, 2018): D465–70. https://doi.org/10.1093/nar/gkx1085.
  36. ^ Merlin, Jerlin C., Sanguthevar Rajasekaran, Tian Mi, and Martin R. Schiller. “Reducing False-Positive Prediction of Minimotifs with a Genetic Interaction Filter.” PloS One 7, no. 3 (2012): e32630. https://doi.org/10.1371/journal.pone.0032630.
  37. ^ Rajasekaran, Sanguthevar, Jerlin Camilus Merlin, Vamsi Kundeti, Tian Mi, Aaron Oommen, Jay Vyas, Izua Alaniz, et al. “A Computational Tool for Identifying Minimotifs in Protein-Protein Interactions and Improving the Accuracy of Minimotif Predictions.” Proteins 79, no. 1 (January 2011): 153–64. https://doi.org/10.1002/prot.22868.
  38. ^ Sargeant, David P., Sandeep Deverasetty, Christy L. Strong, Izua J. Alaniz, Alexandria Bartlett, Nicholas R. Brandon, Steven B. Brooks, et al. “The HIVToolbox 2 Web System Integrates Sequence, Structure, Function and Mutation Analysis.” PloS One 9, no. 6 (2014): e98810. https://doi.org/10.1371/journal.pone.0098810.
  39. ^ Sargeant, David P., Michael W. Hedden, Sandeep Deverasetty, Christy L. Strong, Izua J. Alaniz, Alexandria N. Bartlett, Nicholas R. Brandon, et al. “The Geogenomic Mutational Atlas of Pathogens (GoMAP) Web System.” PloS One 9, no. 3 (2014): e92877. https://doi.org/10.1371/journal.pone.0092877.
  40. ^ Strong, Christy L., Horacio P. Guerra, Kiran R. Mathew, Nervik Roy, Lacy R. Simpson, and Martin R. Schiller. “Damaging the Integrated HIV Proviral DNA with TALENs.” PloS One 10, no. 5 (2015): e0125652. https://doi.org/10.1371/journal.pone.0125652.
  41. ^ Benjamin, Ronald, Bradford K. Berges, Antonio Solis-Leal, Omoyemwen Igbinedion, Christy L. Strong, and Martin R. Schiller. “TALEN Gene Editing Takes Aim on HIV.” Human Genetics 135, no. 9 (May 12, 2016): 1059–70. https://doi.org/10.1007/s00439-016-1678-2.
  42. ^ Rajasekaran, Sanguthevar, Tian Mi, Jerlin Camilus Merlin, Aaron Oommen, Patrick Gradie, and Martin R. Schiller. “Partitioning of Minimotifs Based on Function with Improved Prediction Accuracy.” PloS One 5, no. 8 (August 19, 2010): e12276. https://doi.org/10.1371/journal.pone.0012276.
  43. ^ Giacoletto, Christopher J., and Martin R. Schiller. “The History and Conceptual Framework of Assays and Screens.” BioEssays 45, no. 4 (April 2023): 2200191. https://doi.org/10.1002/bies.202200191.
  44. ^ Derbel, Houssemeddine, Christopher J. Giacoletto, Ronald Benjamin, Gordon Chen, Martin R. Schiller, and Qian Liu. “Accurate Prediction of Transcriptional Activity of Single Missense Variants in HIV Tat with Deep Learning.” International Journal of Molecular Sciences 24, no. 7 (March 24, 2023): 6138. https://doi.org/10.3390/ijms24076138.
  45. ^ Benjamin, Ronald, Chrisopher Giacoletto, Zachary FitzHugh, Danielle Eames, Lindsay Buczek, Xiagong Wu, Jacklyn Newsome, et al. “Data Supporting a Saturation Mutagenesis Assay for Tat-Driven Transcription with the GigaAssay.” Data in Brief 45 (2022): 108641. https://doi.org/10.1016/j.dib.2022.108641.
  46. ^ Benjamin, Ronald, Christopher J. Giacoletto, Zachary T. FitzHugh, Danielle Eames, Lindsay Buczek, Xiaogang Wu, Jacklyn Newsome, et al. “GigaAssay – An Adaptable High-Throughput Saturation Mutagenesis Assay Platform.” Genomics 114, no. 4 (July 2022): 110439. https://doi.org/10.1016/j.ygeno.2022.110439.
  47. ^ Heligenics. “Heligenics: Fulfilling the Promise of the Functional Genome to Enable Precision Medicine.” Nature Biopharma Dealmakers (Biopharm Deal) (April 2023).
  48. ^ Giacoletto, Christopher J., Ronald Benjamin, Hong-Wen Deng, Jerome I. Rotter, and Martin R. Schiller. “Most Synonymous Allelic Variants in HIV Tat Are Not Silent.” Genomics 115, no. 3 (May 2023): 110603. https://doi.org/10.1016/j.ygeno.2023.110603.
  49. ^ Giacoletto, Christopher J., Jerome I. Rotter, Wayne W. Grody, and Martin R. Schiller. “Synonymous Variants of Uncertain Silence.” International Journal of Molecular Sciences 24 (2023): 10556. https://doi.org/10.3390/ ijms241310556.
  50. ^ Schiller, M, and J Busch. “Reinheitsgebot and the Fifth Ingredient | MoreBeer.” Accessed September 20, 2024. https://www.morebeer.com/articles/Reinheitsgebot_Fifth_Ingredient.
  51. ^ Nilsson, Pascal D., Jacklyn M. Newsome, Henry M. Santos, and Martin R. Schiller. “Prioritization of Variants for Investigation of Genotype-Directed Nutrition in Human Superpopulations.” International Journal of Molecular Sciences 20, no. 14 (July 18, 2019): E3516. https://doi.org/10.3390/ijms20143516.
  52. ^ Benjamin, Ronald, Chrisopher Giacoletto, Zachary FitzHugh, Danielle Eames, Lindsay Buczek, Xiagong Wu, Jacklyn Newsome, et al. “Data Supporting a Saturation Mutagenesis Assay for Tat-Driven Transcription with the GigaAssay.” Data in Brief 45 (2022): 108641. https://doi.org/10.1016/j.dib.2022.108641.
  53. ^ Benjamin, Ronald, Christopher J. Giacoletto, Zachary T. FitzHugh, Danielle Eames, Lindsay Buczek, Xiaogang Wu, Jacklyn Newsome, et al. “GigaAssay – An Adaptable High-Throughput Saturation Mutagenesis Assay Platform.” Genomics 114, no. 4 (July 2022): 110439. https://doi.org/10.1016/j.ygeno.2022.110439.
  54. ^ Derbel, Houssemeddine, Christopher J. Giacoletto, Ronald Benjamin, Gordon Chen, Martin R. Schiller, and Qian Liu. “Accurate Prediction of Transcriptional Activity of Single Missense Variants in HIV Tat with Deep Learning.” International Journal of Molecular Sciences 24, no. 7 (March 24, 2023): 6138. https://doi.org/10.3390/ijms24076138.
  55. ^ Heligenics. “Heligenics: Fulfilling the Promise of the Functional Genome to Enable Precision Medicine.” Nature Biopharma Dealmakers (Biopharm Deal) (April 2023).




Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Martin_R._Schiller&oldid=1248984782"